![]() AKI occurs in up to half of all patients admitted to the ICU, and of these patients, 4-13% require RRT. Renal replacement therapy (RRT) is often required to treat critically ill patients with acute kidney injury (AKI) or end-stage kidney disease (ESKD) in the intensive care unit (ICU). Tablo’s prolonged therapy meets the needs of critically patients, including COVID-19 positive patients, requiring renal replacement therapy for greater than 12 h. This data demonstrates the effectiveness of Tablo in achieving personalization of treatments necessary for unstable patients and enabling successful delivery of extended therapy with minimal clotting. Tablo successfully achieves prescribed treatment time with minimal therapy interruptions from alarms or cartridge changes. Blood pump stoppage time was higher in the COVID-19 subgroup when compared to the non-COVID-19 subgroup. Median blood pump stoppage time related to these alarms was 2.3 min per treatment. The dialysis treatment time was delivered in 91% of treatments, with 6% ending early due to an alarm, and 3% ending due to clotting.Ĭlinically significant alarms occurred at a median rate of 0.5 per treatment hour with a resolution time of 18 s. Median cartridge usage was 1.3 per treatment. One hundred (100) consecutive Tablo prolonged treatments had a median prescribed treatment time of 24 h and a median achieved treatment time of 21.3 h. Sub-group analysis between COVID-19 positive and negative patients were reported. Dialysis treatment delivery, clinically significant alarms, and clotting events were recorded. After a run-in period of five treatments, Tablo data were collected via real-time transmission to a cloud-based, HIPAA compliant platform and reviewed by site staff. Nursing staff were trained during a single training session on Tablo prolonged therapy. The objective is to report on the first ever experience with Tablo prolonged therapy between 12 and 24 h in critically ill patients treated at a single-center ICU. Extension of the Tablo cartridge to 24 h allows prolonged therapy and even greater flexibility for prescribers in the acute setting. Prior reports have demonstrated Tablo’s ability to achieve clinical goals, seamlessly integrate into hospitals and reduce cost across a wide range of treatment times. The Tablo® Hemodialysis System (Tablo) is an all in one, easy-to-learn device featuring integrated water purification, on demand dialysate production and two-way wireless data transmission and is approved for use in the acute, chronic, and home settings.
0 Comments
Leave a Reply. |